Value-Added Medicines

Following its recently announced leadership changes, Hyloris has made two announcements linked to the marketing of its combined pain therapy Maxigesic IV in Brazil and the US.

Marking the firm’s second launch of a 505(b)(2) injectable this year, Amneal has released Focinvez in the US as an antiemetic agent used in chemotherapy regimens.

An additional week has been added to the deadline for companies to submit their entries for the Global Generics & Biosimilars Awards 2024, ahead of our ceremony in Milan on 9 October.

Marking a further development in the story of Hyloris’ in-licensing deal with QliniQ, the company’s board has announced significant leadership and organizational changes to address potential concerns.

UK liquids specialist Rosemont Pharmaceuticals has delivered on promises to expand into the US market by striking a deal to acquire Georgia-based distributor Sabal Therapeutics.

Altus’ breakable extended-release tablet technology will be Spektus’ holy grail in developing novel and differentiated therapies in the psychiatry space.

Generics Bulletin previews the most noteworthy and anticipated events for July 2024.

Just one month remains for companies to submit their entries to the Global Generics & Biosimilars Awards 2024, ahead of our ceremony in October.

Having earlier this year outlined plans for international expansion, liquids specialist Rosemont has made its first venture outside the UK by acquiring Greek R&D organization Pharma-Data.

At a panel on value added medicines at Medicines for Europe’s 30th annual conference in Dublin last week, Pharmanovia CEO and value added medicines sector chair James Burt set out the case for expanding the scope of current EU pharma legislation proposals to reward reformulation alongside repurposing.

At Medicines for Europe’s 30th annual conference in Dublin last week, the European association and its Irish counterpart provided an overview of the challenges and opportunities facing the European off-patent industry.

Outlook Therapeutics has revealed more details of its European launch strategy for its Lytenava ophthalmic bevacizumab following the product’s formal European Commission approval.

Generics Bulletin previews the most noteworthy and anticipated events for June 2024.

Medicines for Ireland has called for action that would alleviate drug shortages affecting every fifth patient in the country after recently urging strategic reform in the EU.

Viatris has revealed the early stages of a battle plan after it was knocked back on US FDA approval for its proposed once-monthly glatiramer acetate ‘GA Depot’ product, a follow-on to Teva’s Copaxone treatment for relapsing forms of multiple sclerosis.

Celebrating positive trial results for its long-acting injectable olanzapine, at the same time as reporting across-the-board growth for its generics business in Q1, Teva says it is pushing forward with its “pivot to growth” strategy almost a year after it was introduced by CEO Richard Francis.